MIGENIX Reports Effectiveness of MX-2401 in Pneumonia Model
In studies conducted by Dr. William Craig at the University of Wisconsin Medical School and the VA Medical Center, the ability of MX-2401 to kill Streptococcus pneumoniae in the lungs and/or thighs of infected mice (a model used widely to predict efficacy in human pneumonia and complicated skin and soft tissue infections) and the efficacy of MX-2401 against another serious gram-positive pathogen, Staphylococcus aureus were confirmed. Dr. Craig is an internationally recognized expert in anti-infective therapy and Head of Clinical Pharmacology at the University of Wisconsin Medical School and a member of the MIGENIX Clinical Advisory Board.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.